Sartorius (0NIR) AI Stock Analysis

7 Followers

Sartorius

(LSE:0NIR)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring Bioprocess RevenueThe mix of replenishable single-use and filtration products can create repeat purchasing linked to customers’ production volumes. This recurring element gives Sartorius a more durable revenue base than a business dependent only on occasional equipment sales and supports customer retention over multiple production cycles.

Negative Factors

Modest Revenue GrowthLow-single-digit revenue growth shows that the recovery in demand has not yet translated into a strong expansion of the top line. Remaining below the 2022 peak suggests customer investment cycles and product mix have not fully normalized, limiting near-term operating leverage and growth visibility.

Sartorius (0NIR) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 17.89B
Dividend Yield: 0.25%
Average Volume (3M): 29.06K
Price to Earnings (P/E): 72.5
Beta (1Y): 1.43
Revenue Growth: 4.19%
EPS Growth: 63.32%
Country: UK
Employees: 14,273
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Sartorius Business Overview & Revenue Model

Company Description

Sartorius AG is a global supplier of advanced bioprocess and laboratory solutions, offering a comprehensive portfolio of products and services essential for life science research and biopharmaceutical manufacturing. The company's offerings include so...

Sartorius Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GB:0NIR against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:G1A	80Outperform	EUR 11.67B	26.99	17.46%	1.78%	5.37%	9.46%
DE:AFX	73Outperform	EUR 3.02B	20.60	5.52%	1.60%	-0.06%	-38.81%
DE:PFV	59Neutral	EUR 1.59B	23.55	12.29%	4.52%	0.35%	116.73%
DE:SBS	57Neutral	EUR 303.90M	-653.75	-0.17%	2.29%	―	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:GXI	52Neutral	EUR 1.08B	-2.75	-32.84%	0.13%	8.90%	-609.05%

* General Sector Average

Performance Comparison

GB:0NIR and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0NIR	Sartorius AG	294.60	63.89	27.69%
DE:AFX	Carl Zeiss Meditec	34.40	-8.26	-19.36%
DE:G1A	GEA Group AG	73.15	15.45	26.77%
DE:GXI	Gerresheimer AG	31.92	7.06	28.40%
DE:PFV	Pfeiffer Vacuum Technology	162.00	12.69	8.50%
DE:SBS	STRATEC Biomedical	26.15	5.61	27.31%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sartorius AI Stock Analysis